KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Net Margin (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Net Margin for 16 consecutive years, with 31.35% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin fell 7732.0% to 31.35% in Q4 2025 year-over-year; TTM through Dec 2025 was 22.69%, a 2105.0% decrease, with the full-year FY2025 number at 22.69%, down 2105.0% from a year prior.
  • Net Margin was 31.35% for Q4 2025 at Halozyme Therapeutics, down from 49.47% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 67.02% in Q2 2021 to a low of 69.15% in Q3 2021.
  • A 5-year average of 32.07% and a median of 38.55% in 2024 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: tumbled -12458bps in 2021, then surged 9864bps in 2022.
  • Halozyme Therapeutics' Net Margin stood at 65.46% in 2021, then plummeted by -51bps to 31.79% in 2022, then grew by 17bps to 37.12% in 2023, then increased by 24bps to 45.98% in 2024, then tumbled by -168bps to 31.35% in 2025.
  • Per Business Quant, the three most recent readings for HALO's Net Margin are 31.35% (Q4 2025), 49.47% (Q3 2025), and 50.7% (Q2 2025).